{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T17:26:13Z","timestamp":1785000373853,"version":"3.55.0"},"reference-count":12,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2018,7,12]]},"DOI":"10.1001\/jamaoncol.2017.3695","type":"journal-article","created":{"date-parts":[[2017,11,22]],"date-time":"2017-11-22T17:31:30Z","timestamp":1511371890000},"page":"e173695","source":"Crossref","is-referenced-by-count":62,"title":["Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With<i>RAS<\/i>and<i>BRAF<\/i>Mutational Status"],"prefix":"10.1001","volume":"4","author":[{"given":"Julien","family":"Taieb","sequence":"first","affiliation":[{"name":"Sorbonne Paris Cit\u00e9, Universit\u00e9 Paris Descartes, Department of Hepatogastroenterology and GI Oncology, H\u00f4pital Europ\u00e9en Georges Pompidou, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hampig Raphael","family":"Kourie","sequence":"additional","affiliation":[{"name":"Sorbonne Paris Cit\u00e9, Universit\u00e9 Paris Descartes, Department of Hepatogastroenterology and GI Oncology, H\u00f4pital Europ\u00e9en Georges Pompidou, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Emile","sequence":"additional","affiliation":[{"name":"Pathology Department, Ambroise Par\u00e9 Hospital, Boulogne-Billancourt, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Le Malicot","sequence":"additional","affiliation":[{"name":"F\u00e9d\u00e9ration Francophone de Canc\u00e9rologie Digestive (FFCD), Dijon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralyath","family":"Balogoun","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Descartes, Sorbonne Paris Cit\u00e9, France"},{"name":"Assistance Publique\u2013H\u00f4pitaux de Paris, Department of Biology, H\u00f4pital Europ\u00e9en Georges Pompidou, INSERM UMR-S1147, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Tabernero","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Vall d\u2018Hebron University Hospital and Institute of Oncology (VHIO), CIBERONC, Universitat Aut\u00f2noma de Barcelona, Spanish Gastrointestinal Tumours TTD Group, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Mini","sequence":"additional","affiliation":[{"name":"Section of Internal Medicine, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Folprecht","sequence":"additional","affiliation":[{"name":"Medical Department I, University Hospital Carl Gustav Carus, Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Luc","family":"Van Laethem","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, H\u00f4pital Universitaire Erasme, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Mulot","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Descartes, Sorbonne Paris Cit\u00e9, France"},{"name":"Assistance Publique\u2013H\u00f4pitaux de Paris, Department of Biology, H\u00f4pital Europ\u00e9en Georges Pompidou, INSERM UMR-S1147, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Bouch\u00e9","sequence":"additional","affiliation":[{"name":"Department of Hepato-Gastroenterology, Reims University Hospital, Reims, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Aparicio","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, CHU Saint Louis, Assistance Publique\u2013H\u00f4pitaux de Paris and Universit\u00e9 Paris 7, Sorbonne Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Michel","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Rouen University Hospital, University of Rouen, Rouen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef","family":"Thaler","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine IV, Klinikum Wels-Grieskirchen, Wels, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Bridgewater","sequence":"additional","affiliation":[{"name":"UCL Cancer Institute, University College London, London, England"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Van Cutsem","sequence":"additional","affiliation":[{"name":"Digestive Oncology, University Hospitals Leuven and KU Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9raldine","family":"Perkins","sequence":"additional","affiliation":[{"name":"Digestive Oncology, University Hospitals Leuven and KU Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Come","family":"Lepage","sequence":"additional","affiliation":[{"name":"F\u00e9d\u00e9ration Francophone de Canc\u00e9rologie Digestive (FFCD), Dijon, France"},{"name":"Hepato-Gastroenterology Department, Dijon University Hospital and INSERM U 866, Dijon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramon","family":"Salazar","sequence":"additional","affiliation":[{"name":"Catalan Institute of Oncology (IDIBELL), Universitat de Barcelona, CIBERONC, Spanish Gastrointestinal Tumours TTD Group, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Laurent-Puig","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Descartes, Sorbonne Paris Cit\u00e9, France"},{"name":"Assistance Publique\u2013H\u00f4pitaux de Paris, Department of Biology, H\u00f4pital Europ\u00e9en Georges Pompidou, INSERM UMR-S1147, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Pan-European Trials in Alimentary Tract Cancer (PETACC)-8 Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"5","key":"cbr170029r1","doi-asserted-by":"publisher","first-page":"djw272","DOI":"10.1093\/jnci\/djw272","article-title":"Prognostic value of BRAF and KRAS mutations in MSI and MSS stage III colon cancer.","volume":"109","author":"Taieb","year":"2016","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"cbr170029r2","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1093\/annonc\/mdx175","article-title":"Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials.","volume":"28","author":"Arnold","year":"2017","journal-title":"Ann Oncol"},{"issue":"8","key":"cbr170029r3","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/S1470-2045(14)70227-X","article-title":"Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.","volume":"15","author":"Taieb","year":"2014","journal-title":"Lancet Oncol"},{"key":"cbr170029r4","article-title":"Prognostic effect of BRAF and KRAS mutations in patients with stage III colon cancer treated with leucovorin, fluorouracil, and oxaliplatin with or without cetuximab: a post hoc analysis of the PETACC-8 trial. [Published online January 14, 2016].","author":"Taieb","journal-title":"JAMA Oncol"},{"issue":"4","key":"cbr170029r5","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1093\/annonc\/mdw687","article-title":"Adjuvant FOLFOX +\/- cetuximab in full RAS and BRAF wildtype stage III colon cancer patients.","volume":"28","author":"Taieb","year":"2017","journal-title":"Ann Oncol"},{"issue":"1","key":"cbr170029r6","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/DCR.0b013e3181c703a4","article-title":"Comparison of 17,641 patients with right- and left-sided colon cancer: differences in epidemiology, perioperative course, histology, and survival.","volume":"53","author":"Benedix","year":"2010","journal-title":"Dis Colon Rectum"},{"issue":"5","key":"cbr170029r7","doi-asserted-by":"publisher","first-page":"e002608","DOI":"10.1136\/bmjopen-2013-002608","article-title":"A nationwide Danish cohort study challenging the categorisation into right-sided and left-sided colon cancer.","volume":"3","author":"Jess","year":"2013","journal-title":"BMJ Open"},{"issue":"15","key":"cbr170029r8","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1200\/JCO.2016.34.15_suppl.3504","article-title":"Impact of primary (1\u00b0) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): analysis of CALGB\/SWOG 80405 (Alliance).","volume":"34","author":"Venook","year":"2016","journal-title":"J Clin Oncol"},{"issue":"15","key":"cbr170029r9","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.1200\/jco.2014.32.15_suppl.3600","article-title":"Gender and tumor location as predictors for efficacy: influence on endpoints in first-line treatment with FOLFIRI in combination with cetuximab or bevacizumab in the AIO KRK 0306 (FIRE3) trial.","volume":"32","author":"Heinemann","year":"2014","journal-title":"J Clin Oncol"},{"issue":"31","key":"cbr170029r10","doi-asserted-by":"publisher","first-page":"4697","DOI":"10.1200\/JCO.2009.27.4860","article-title":"Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.","volume":"28","author":"Douillard","year":"2010","journal-title":"J Clin Oncol"},{"issue":"21","key":"cbr170029r11","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1200\/JCO.2013.53.2473","article-title":"PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer.","volume":"32","author":"Schwartzberg","year":"2014","journal-title":"J Clin Oncol"},{"issue":"11","key":"cbr170029r12","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1038\/nm.3967","article-title":"The consensus molecular subtypes of colorectal cancer.","volume":"21","author":"Guinney","year":"2015","journal-title":"Nat Med"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2663951","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T15:34:46Z","timestamp":1603380886000},"score":1,"resource":{"primary":{"URL":"http:\/\/oncology.jamanetwork.com\/article.aspx?doi=10.1001\/jamaoncol.2017.3695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,12]]},"references-count":12,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2017.3695","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7,12]]}}}